Argenx

This study is testing whether a new drug called empasiprubart works as well as or better than the current standard treatment (IVIg) for adults with multifocal motor neuropathy (MMN), a rare condition that causes muscle weakness. About 115 participants will be randomly assigned to…

This study is testing how well a drug called efgartigimod PH20 SC, given as an injection under the skin, works for adults newly diagnosed with generalized myasthenia gravis (gMG). It will measure if the treatment can help patients achieve minimal symptoms and improve their daily …

This study is testing whether a new injectable medication called efgartigimod can reduce disease activity and symptoms in adults with moderate-to-severe primary Sjögren's disease. About 580 participants will receive either the active drug or a placebo injection for 48 weeks, foll…

This is an early-stage study to check the safety and side effects of an experimental drug called ARGX-119 in adults with a rare genetic muscle disorder (DOK7-CMS). The study will also see how the body processes the drug and if it helps improve patients' strength and daily functio…

This study is testing a medication called efgartigimod in children and teenagers with generalized myasthenia gravis, a rare autoimmune disease that causes severe muscle weakness. The trial aims to find the right dose for young patients and see how safe and effective it is at cont…

This study aims to understand how well a medication called efgartigimod works for people with CIDP in real-world settings, outside of a controlled clinical trial. It will follow 200 adults with CIDP for up to two years after they start this treatment, tracking their symptoms, dai…

This study aims to find the right dose and check the safety of an investigational injection called efgartigimod for children and teenagers (ages 2 to under 18) with generalized myasthenia gravis (gMG), a rare autoimmune disease that causes severe muscle weakness. Participants wil…

This study is testing whether adding a new drug called empasiprubart to an existing treatment (efgartigimod) can better control symptoms of myasthenia gravis. It will involve about 70 adults with a specific type of this muscle-weakening disease who have had only a partial improve…

This study aims to test the safety and effectiveness of several different drug combinations for people with myasthenia gravis, a condition that causes muscle weakness. It will enroll about 70 adults who have been diagnosed with the disease and are on stable treatment. The goal is…

This program provides early access to an investigational treatment called efgartigimod PH20 SC for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder. It's designed for patients who can't join regular clinical trials and haven't found relief fr…

This Phase 3 study is testing whether an intravenous medication called efgartigimod can safely and effectively raise and maintain platelet counts in adults with chronic primary immune thrombocytopenia (ITP). About 69 participants will be randomly assigned to receive either the st…

This study is testing whether a new injectable drug called efgartigimod can help control antibody-mediated rejection in people who have received a kidney transplant. About 30 participants will receive either the drug or a placebo via a prefilled syringe for 48 weeks while continu…

This study is testing a drug called efgartigimod in teenagers (12 to under 18 years old) who have chronic immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets. The main goal is to find the correct dose and see if it helps increase and maintai…

This study aims to see if a new intravenous drug called empasiprubart works as well as or better than the current standard treatment (IVIg) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness. For the first 6 months, par…

This study is testing whether a drug called efgartigimod, given as an injection under the skin, can help control the disease in adults with systemic sclerosis (scleroderma). About 81 participants will receive either the drug or a placebo for up to 48 weeks to see if it reduces sk…

This study is testing whether an investigational medicine called empasiprubart is safe and can help adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a nerve disorder that causes weakness and disability. For the first 6 months, some participants will receive t…

This study is testing a new drug called ARGX-119 in children aged 5 to 18 with spinal muscular atrophy (SMA). The goal is to see if the drug is safe and if it can improve muscle strength and walking ability when given along with the child's current SMA treatments. For the first 2…

This study aims to monitor the long-term safety of the approved drug efgartigimod in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It will enroll about 680 patients, comparing those taking the drug to similar patients who are not. The m…

This study aims to understand the safety of the medication efgartigimod during pregnancy and breastfeeding. It will follow women with conditions like myasthenia gravis who were exposed to the drug around conception, during pregnancy, or while nursing. Researchers will track pregn…

This early-stage study aims to check the safety of a new drug called ARGX-124 in healthy adults. Researchers will measure how much of the drug stays in the blood and how the body's immune system reacts to it. The study will involve about 104 healthy volunteers who will be monitor…

This study aims to learn more about Congenital Myasthenic Syndrome (CMS), a rare genetic muscle-weakening disorder. Researchers will observe up to 100 participants with specific genetic types of CMS over several visits, tracking their symptoms, daily function, and quality of life…

This early-stage study aims to check if a new drug called ARGX-213 is safe for people. It will involve 80 healthy adults who will receive either the drug or a placebo. Researchers will track side effects and measure how the drug moves through the body over about 21 weeks.